Worth Observing Stocks: Tribune Media Company (NYSE:TRCO), Juno Therapeutics Inc. (NASDAQ:JUNO)

Tribune Media Company (NYSE:TRCO)

The company announced its last quarter financial performance results on 11/09/2016. Tribune Media Company (NYSE:TRCO) belongs to Consumer Discretionary sector that surged 0.8% in value when last trading session closed at $32.75. The company has a market capitalization of $2.95 Billion. The company’s stock has a Return on Assets (ROA) of 0.1 percent, a Return on Equity (ROE) of 0.2 percent and Return on Investment (ROI) of -4.4 percent. The company reached its 52-Week high of $40.72 on May 26, 2016 and 52-Week low of $27.75 on Jan 27, 2017.

Earnings per share (ttm) for Tribune Media Company (NYSE:TRCO) according to Finviz Data is $-4.12.

The growth estimate for Tribune Media Company (NYSE:TRCO) for the current quarter is 122.6 percent. The projected growth estimate for the next quarter is 33.3 percent. The company’s stock has grown by -21.95 percent in the past 5 years. For the next 5 years, the company is expected to grow by 3 percent.

This company was Downgrade by Morgan Stanley on 1-Jun-16  to Underweight.

The 5 analysts offering 12-month price forecasts for Tribune Media Co have a median target of 31.00, with a high estimate of 54.00 and a low estimate of 27.00. The median estimate represents a -5.34% decrease from the last price of 32.75.

Financial History:

Following Earnings result, share price were UP 4 times out of last 8 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 41% percent of times. It has met expectations  1 times and missed earnings  6  times.

The consensus recommendation for Tribune Media Company (NYSE:TRCO) is 2.14. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.4. In comparison, the consensus recommendation 60 days ago was at 2.4, and 90 days ago was at 2.4 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Tribune Media Company to have earnings per share of $0.92.

Revenue is expected to range from 588.13 Million to 604 Million with an average of 596.76 Million.

Company Profile:

Tribune Media Company is engaged in broadcast distribution, digital properties and data businesses. The company provides Antenna TV, THIS TV, radio station, music and video content and technologies. It also owns and manages real estate properties. Tribune Media Company, formerly known as Tribune Company, is based in Chicago, Illinois.

Juno Therapeutics Inc. (NASDAQ:JUNO):

Juno Therapeutics Inc. (NASDAQ:JUNO) belongs to Medical sector closed its last session with a loss of -3.05 percent and closed its previous trading session at $23.23. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-2.81. The company has the Market capitalization of $2.43 Billion. The company’s stock has a Return on Assets (ROA) of -19 percent, a Return on Equity (ROE) of -24 percent and Return on Investment (ROI) of -20.3 percent. The company reached its 52-Week high of $49.72 on Jun 6, 2016 and 52-Week low of $17.52 on Dec 22, 2016.

This company was Initiated by Wedbush on 2-Feb-17 to Neutral.

The 11 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 34.00, with a high estimate of 41.00 and a low estimate of 24.00. The median estimate represents a +46.36% increase from the last price of 23.23.

Financial History:

Following Earnings result, share price were UP 5 times out of last 8 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Juno Therapeutics Inc. (NASDAQ:JUNO) is 2.4. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.33. In comparison, the consensus recommendation 60 days ago was at 1.9, and 90 days ago was at 1.78 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Juno Therapeutics Inc. to have earnings per share of $-0.61.

Revenue is expected to range from 7.5 Million to 20.3 Million with an average of 14.57 Million.

Company Profile:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

You may missed